120 related articles for article (PubMed ID: 19761489)
1. In vitro efficacy of amphotericin B, 5-fluorocytosine, fluconazole, voriconazole and posaconazole against Candida dubliniensis isolates using time-kill methodology.
Szabo Z; Borbely A; Kardos G; Somogyvari F; Kemény-Beke A; Asztalos L; Rozgonyi F; Majoros L
Mycoses; 2010 May; 53(3):196-9. PubMed ID: 19761489
[TBL] [Abstract][Full Text] [Related]
2. In vitro efficacy of 5 antifungal agents against Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis as determined by time-kill methodology.
Szabó Z; Szilágyi J; Tavanti A; Kardos G; Rozgonyi F; Bayegan S; Majoros L
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):283-8. PubMed ID: 19394787
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.
Lignell A; Löwdin E; Cars O; Sjölin J
J Antimicrob Chemother; 2008 Jul; 62(1):142-8. PubMed ID: 18408237
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
6. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
7. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
8. Patterns of amphotericin B killing kinetics against seven Candida species.
Cantón E; Pemán J; Gobernado M; Viudes A; Espinel-Ingroff A
Antimicrob Agents Chemother; 2004 Jul; 48(7):2477-82. PubMed ID: 15215097
[TBL] [Abstract][Full Text] [Related]
9. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
Lee SC; Lo HJ; Fung CP; Lee N; See LC
J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
[TBL] [Abstract][Full Text] [Related]
12. [In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata].
Blanco MT; Cañadas J; García-Martos P; Marín P; García-Tapia A; Rodríguez J
Rev Esp Quimioter; 2009 Sep; 22(3):139-43. PubMed ID: 19662547
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
15. Antifungal susceptibility of clinical Candida parapsilosis isolates in Kuwait.
Asadzadeh M; Al-Sweih NA; Ahmad S; Khan ZU
Mycoses; 2008 Jul; 51(4):318-23. PubMed ID: 18855844
[TBL] [Abstract][Full Text] [Related]
16. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
17. Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology.
Földi R; Szilágyi J; Kardos G; Berényi R; Kovács R; Majoros L
Diagn Microbiol Infect Dis; 2012 Aug; 73(4):338-42. PubMed ID: 22726529
[TBL] [Abstract][Full Text] [Related]
18. Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3.
Varga I; Sóczó G; Kardos G; Majoros L
J Antimicrob Chemother; 2008 Jul; 62(1):149-52. PubMed ID: 18390882
[TBL] [Abstract][Full Text] [Related]
19. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
